Australia's most trusted
source of pharma news
Friday, 18 July 2025
Posted 16 July 2025 AM
It may only be a matter of weeks until three blockbuster franchises, worth a combined $924 million face their first rivals on the PBS.
Sandoz has already announced that it expects Jubbonti and Wyost will be added to the PBS next month, which would mark the first biosimilars of Amgen’s Prolia and Xgeva, respectively. However, Amgen started legal proceedings against Sandoz to protect its franchise in April.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.